Next-generation triple agonist peptide for comprehensive weight management and metabolic optimization research.
Significant weight loss through triple receptor agonism
Improved insulin sensitivity and glucose metabolism
Reduced appetite and improved satiety signaling
Support for cardiovascular and liver health
This product is intended for laboratory research purposes only. Not for human consumption or clinical use. All purchases require consultation with a qualified healthcare provider. Retatrutide has not been evaluated by the FDA.
Have questions about Retatrutide or need personalized guidance? We're here to help with any inquiries about this product.
Email Us About This ProductWe typically respond within 24 hours
Retatrutide (LY3437943) is a novel triple agonist peptide that simultaneously targets the GLP-1, GIP, and glucagon receptors. This unique mechanism of action makes it one of the most promising peptides in development for weight management and metabolic health research.
As a research compound, Retatrutide has shown remarkable results in preclinical and clinical studies, demonstrating significant weight loss, improved insulin sensitivity, and beneficial effects on cardiovascular risk markers. Its triple receptor targeting sets it apart from single-agonist peptides.
Our Retatrutide is supplied as a lyophilized powder for research use only, with full Certificates of Analysis available for all batches.
Reduces hunger signals and promotes satiety through gut-brain communication.
Enhances glucose metabolism and energy expenditure in adipose tissue.
Increases caloric burn through direct effects on liver and fat metabolism.